Trust signals
> Written by the FormBlends Medical Content Team · Fact-checked against cited primary sources · Last updated May 2026
The molecular promise and human reality of 5-amino-1MQ
5-amino-1-methylquinolinium entered the NAD+ booster conversation through a compelling 2018 mouse study. Researchers demonstrated that blocking NNMT with this small molecule could reshape metabolism in obese mice, reducing fat mass by over a third while improving insulin sensitivity. The compound works by preventing the breakdown of nicotinamide, theoretically preserving more substrate for NAD+ synthesis.
Yet translating these results to humans faces a fundamental barrier: the molecule's permanent positive charge. This quaternary ammonium structure, while excellent for enzyme binding, creates an absorption nightmare. Similar charged compounds achieve less than 10% oral bioavailability, often closer to 2 to 5%. No published human pharmacokinetic data exists to confirm whether oral 5-amino-1MQ reaches therapeutic tissue levels.
The market has rushed ahead anyway. Suppliers offer 50 to 100mg capsules based on rough extrapolations from mouse injection doses. At $3 to 8 per dose, users pay premium prices for a compound that may never escape their digestive tract in meaningful quantities.
Understanding NNMT: More than just NAD+ metabolism
Nicotinamide N-methyltransferase occupies a curious position in cellular biochemistry. Beyond its role in NAD+ turnover, NNMT methylates drugs, environmental toxins, and bioactive compounds. Cancer researchers know it well, as many tumors overexpress NNMT, potentially using it to evade certain therapies.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →5-amino-1MQ competitively inhibits human NNMT with an IC50 of 5.3μM in biochemical assays. This potency sounds impressive until you consider tissue penetration requirements. Achieving micromolar concentrations throughout metabolically active tissues requires either excellent bioavailability or massive doses.
The enzyme shows distinct tissue distribution patterns between species. Mouse NNMT concentrates in liver and fat. Human NNMT spreads more broadly, with significant expression in brain, muscle, kidney, and other organs. This distribution difference alone suggests mouse metabolic results may not predict human responses.
Dissecting the landmark mouse research
The University of Texas team's 2018 study provides the foundation for virtually all 5-amino-1MQ marketing claims. They administered 20mg/kg daily via intraperitoneal injection to diet-induced obese mice for 11 days. Results included:
- 35% reduction in fat mass
- 30% reduction in total body weight
- Improved glucose tolerance
- Increased energy expenditure
- No apparent toxicity
Critical details often omitted: researchers used injection, not oral administration. The 11-day treatment period tells us nothing about long-term safety. Diet-induced obese C57BL/6 mice represent a specific metabolic model that doesn't capture human obesity complexity.
Most importantly, the tissue concentrations achieved through injection likely exceed what oral dosing could ever accomplish. Intraperitoneal injection provides near-complete bioavailability. Oral administration of a charged molecule might achieve 5% if formulated expertly.
Current dosing practices lack scientific foundation
Market doses of 50 to 100mg daily appear to derive from simple allometric scaling of the mouse data. This calculation assumes equal bioavailability between injection and oral routes, ignoring fundamental pharmaceutical principles.
A proper translation would require:
- Human pharmacokinetic studies establishing oral bioavailability
- Dose-ranging trials to identify therapeutic thresholds
- Tissue distribution data confirming target engagement
- Safety assessment across multiple organ systems
None of this data exists. Users taking 50mg capsules participate in an uncontrolled experiment with unknown efficacy and safety parameters.
The bioavailability wall
Quaternary ammonium compounds face severe absorption challenges. Their permanent positive charge prevents passive diffusion across lipid membranes. Without specific transporters, these molecules remain trapped in the intestinal lumen.
Pharmaceutical companies spend millions developing prodrug strategies or specialized formulations to overcome this barrier. 5-amino-1MQ sellers simply put the raw compound in capsules and hope for the best.
Related compounds provide sobering context. Ipratropium bromide, another quaternary ammonium drug, achieves approximately 2% oral bioavailability. Glycopyrrolate manages 3 to 5%. These medications required extensive formulation development to achieve even these modest levels.
Comparing NAD+ intervention strategies
The NAD+ enhancement field offers multiple approaches with varying levels of evidence:
NMN (nicotinamide mononucleotide) provides direct NAD+ precursor supplementation. Multiple human trials demonstrate 25 to 50% increases in blood NAD+ levels with doses of 250 to 1000mg daily. Oral bioavailability remains variable but sufficient for biological activity.
NR (nicotinamide riboside) follows a similar precursor strategy with better characterized pharmacokinetics. Human studies confirm dose-dependent NAD+ increases, with some formulations achieving 80% bioavailability.
Niacin represents the oldest approach, with decades of human use. Near-complete oral absorption and well-understood safety profile, though flushing limits tolerability.
5-amino-1MQ theoretically offers a complementary mechanism by preventing NAD+ breakdown rather than supplying precursors. Without human data confirming this occurs at achievable tissue concentrations, the theoretical advantage remains purely speculative.
What community experiences reveal
Online peptide communities report mixed experiences with oral 5-amino-1MQ. Common patterns in user reports include minimal noticeable effects at standard doses, with some users escalating to 200 to 300mg daily seeking results. A subset reports mild energy improvements or subtle body composition changes after several weeks, though these anecdotal observations lack controls for diet, exercise, or placebo effects.
More concerning are reports of gastrointestinal discomfort at higher doses, suggesting the compound may irritate the digestive tract when most remains unabsorbed. Some users attempt sublingual administration to bypass first-pass metabolism, though the compound's properties make significant sublingual absorption unlikely.
The research chemical community has begun exploring alternative delivery methods, including intranasal solutions and transdermal preparations. These experimental approaches highlight user frustration with oral delivery but lack safety data or standardization.
Methylation network disruption concerns
NNMT sits at the intersection of multiple metabolic pathways. Blocking it affects more than NAD+ levels:
S-adenosylmethionine (SAM) consumption changes when NNMT inhibition reduces methylation demand. This could theoretically improve methylation capacity elsewhere or disrupt balanced methylation networks.
Drug metabolism alterations remain unstudied. NNMT participates in phase II metabolism of various compounds. Chronic inhibition might change drug clearance rates or accumulation of methylated metabolites.
Cancer biology raises uncomfortable questions. Many tumors overexpress NNMT, and some research suggests NNMT inhibition could have anti-cancer effects. Conversely, disrupting methylation in healthy cells carries unknown long-term risks.
Quality control in an unregulated market
Third-party testing reveals significant quality variations among 5-amino-1MQ suppliers. Purity ranges from 92 to 99%, with some batches containing unidentified impurities. The compound's hygroscopic nature means it readily absorbs moisture, potentially degrading during storage.
Legitimate certificates of analysis should include:
- HPLC purity assessment with chromatogram
- Mass spectrometry confirmation of molecular weight
- Residual solvent testing
- Microbiological assays
- Heavy metal analysis
Many suppliers provide outdated or generic certificates that don't match specific batches. The high price encourages counterfeiting or dilution with inactive fillers.
The economics of unproven promises
At $90 to 240 monthly, 5-amino-1MQ costs significantly more than established NAD+ boosters with human data. This pricing reflects complex synthesis requirements and limited production scale, not proven superior efficacy.
Users pay research chemical prices for a compound that pharmaceutical companies haven't pursued despite patent availability. If oral 5-amino-1MQ delivered dramatic metabolic benefits, pharmaceutical development would likely have proceeded.
Future research requirements
Validating 5-amino-1MQ for human use requires systematic research:
Phase 0 pharmacokinetic studies must establish whether oral dosing achieves meaningful tissue concentrations. If bioavailability proves insufficient, alternative delivery methods need development.
Dose-ranging safety studies should assess methylation markers, liver function, and drug interaction potential across multiple weeks of treatment.
Efficacy trials need proper controls and clinical endpoints beyond self-reported effects. NAD+ levels, metabolic parameters, and body composition changes require objective measurement.
Until this research emerges, 5-amino-1MQ remains an interesting molecular tool that lacks evidence for human therapeutic use.
FAQ
What does 5 amino 1MQ do? 5-amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that breaks down NAD+. By blocking NNMT, it theoretically preserves cellular NAD+ levels. Mouse studies show metabolic benefits, but human oral bioavailability remains unproven.
How much 5-amino-1MQ should I take? Most suppliers recommend 50-100mg oral daily, but no human pharmacokinetic studies validate this dose. The 50mg figure appears extrapolated from mouse studies using 5-20mg/kg injections, not oral dosing.
Does 5-amino-1MQ really work for weight loss? Mouse studies show 35% fat mass reduction with injected 5-amino-1MQ. Zero published human weight loss trials exist. The compound's poor oral bioavailability likely prevents achieving tissue concentrations seen in animal research.
Is 5-amino-1MQ better than NMN? Different mechanisms: NMN directly supplies NAD+ precursors while 5-amino-1MQ blocks NAD+ breakdown. NMN has human trials showing 25% NAD+ increases. 5-amino-1MQ lacks any human NAD+ data.
What are 5-amino-1MQ side effects? No human safety data exists. Mouse studies report no obvious toxicity at therapeutic doses. Theoretical concerns include methylation disruption and unknown drug interactions due to NNMT's role in drug metabolism.
Can I stack 5-amino-1MQ with other peptides? No interaction studies exist. NNMT metabolizes various compounds, so 5-amino-1MQ could theoretically alter other drug levels. Avoid combining without medical supervision.
Why is 5-amino-1MQ so expensive? Complex synthesis requiring multiple steps and purification. Limited manufacturers produce pharmaceutical-grade material. Prices range $200-500 per gram wholesale, translating to $3-8 per 50mg dose.
Is 5-amino-1MQ legal? Not FDA-approved for human use. Sold as research chemical in US. Patent exists but no pharmaceutical development ongoing. Some countries may regulate as unapproved drug.
How long does 5-amino-1MQ take to work? Unknown in humans. Mouse studies show metabolic changes within 7-14 days of injection. Oral administration in humans likely requires longer due to absorption limitations.
Should I take 5-amino-1MQ capsules or powder? Capsules provide accurate dosing and stability. Powder degrades faster when exposed to air and moisture. Neither form solves the fundamental oral bioavailability problem.
Sources
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152.
- Kannt A, et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia. 2015;58(4):799-808.
- Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends Endocrinol Metab. 2017;28(5):340-353.
- Ramsden DB, et al. Nicotinamide N-methyltransferase: genomic connection to disease. Int J Tryptophan Res. 2019;12:1178646919832968.
- Hong S, et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. 2015;21(8):887-894.
Related peptide guides
- 5 amino 1mq overview
- 5 amino 1mq dosage
- 5 amino 1mq before and after
- 5 amino 1mq for sale
- 5 amino 1mq injection
- 5-amino-1mq oral vs injection
- Peptide reconstitution & dosage calculator
Footer disclaimers
Platform: Access to products and treatments mentioned on this page is available solely through FormBlends' physician-supervised telemedicine platform. Eligibility for treatment requires a comprehensive health evaluation as determined by a FormBlends healthcare provider.
Research Compound: 5-amino-1MQ is classified as a research compound. It has not been approved by the FDA for the treatment, diagnosis, or prevention of any disease. All information presented is for educational purposes only and should not be considered medical advice.
Results: Individual results from compounds discussed may vary significantly. The information provided does not guarantee specific outcomes. Always consult with a qualified healthcare professional before beginning any new treatment regimen.
Trademark: FormBlends is a registered trademark. All product names and brands mentioned are the property of their respective owners and are used for identification purposes only.